Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Anti-COVID-19 Traditional Chinese Medicine Database

Author(s): Chao Chen, Rongyu Zhang, Wancheng Wei and Jinming Zhou*

Volume 3, Issue 6, 2022

Published on: 10 November, 2022

Article ID: e281022210454 Pages: 10

DOI: 10.2174/2666796704666221028151334

Open Access Journals Promotions 2
conference banner
Abstract

Background: Novel coronavirus pneumonia COVID-19 has become a serious threat to human health. Traditional Chinese Medicine (TCM) has a good clinical effect in the treatment of COVID-19, with a high effective rate and a low rate of turning to the serious stage.

Objective: We generated the web-accessed anti-COVID-19 TCM database to provide the anti-COVID-19 TCM information to develop effective drugs for the treatment of COVID-19.

Methods: Herein, we collected these prescriptions data by querying the CNKI and Wanfang Chinese databases, the clinical guidance for COVID-19 pneumonia diagnosis and treatment, and further set up the web-accessible anti-COVID-19 TCM database.

Results: Altogether, 293 different prescriptions are applied in four different COVID-19 stages of treatment, and the prevention of COVID-19 is composed of 452 TCM components.

Conclusion: The database provides comprehensive information for anti-COVID TCM and thus would help to investigate novel ways to develop new anti-COVID-19 agents.

Keywords: COVID-19, traditional chinese medicine, database, prescriptions, SARS-CoV-2, pneumonia.

Graphical Abstract

[1]
WHO Coronavirus disease (COVID-19) pandemic. 2022. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2]
Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med 2020; 28(2): 174-84.
[PMID: 32275259]
[3]
Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. First-generation oral antivirals against SARS-CoV-2. Clin Microbiol Infect 2022; 28(9): 1230-5.
[http://dx.doi.org/10.1016/j.cmi.2022.04.015] [PMID: 35545195]
[4]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[5]
Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann Med 2022; 54(1): 516-23.
[http://dx.doi.org/10.1080/07853890.2022.2034936] [PMID: 35118917]
[6]
Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020; 26(6): 808-9.
[http://dx.doi.org/10.1038/s41591-020-0888-2] [PMID: 32488217]
[7]
Vitiello A, La Porta R, Trama U, et al. Pandemic COVID-19, an update of current status and new therapeutic strategies. Naunyn Schmiedebergs Arch Pharmacol 2022; 395(10): 1159-65.
[http://dx.doi.org/10.1007/s00210-022-02265-9] [PMID: 35779085]
[8]
Bhat S, Rishi P, Chadha VD. Understanding the epigenetic mechanisms in SARS-CoV-2 infection and potential therapeutic approaches. Virus Res 2022; 318: 198853.
[http://dx.doi.org/10.1016/j.virusres.2022.198853] [PMID: 35777502]
[9]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new Coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[10]
Li T, Peng T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res 2013; 97(1): 1-9.
[http://dx.doi.org/10.1016/j.antiviral.2012.10.006] [PMID: 23153834]
[11]
Guan W, Lan W, Zhang J, et al. COVID-19: Antiviral agents, antibody development and traditional Chinese medicine. Virol Sin 2020; 35(6): 685-98.
[http://dx.doi.org/10.1007/s12250-020-00297-0] [PMID: 32997322]
[12]
Nebigil CG, Moog C, Vagner S, Benkirane-Jessel N, Smith DR, Désaubry L. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. Eur J Med Chem 2020; 203: 112653.
[http://dx.doi.org/10.1016/j.ejmech.2020.112653] [PMID: 32693294]
[13]
Ti H. Phytochemical profiles and their anti-inflammatory responses against influenza from traditional Chinese medicine or herbs. Mini Rev Med Chem 2021; 20(20): 2153-64.
[http://dx.doi.org/10.2174/1389557520666200807134921] [PMID: 32767941]
[14]
Lee JH, Shu L, Fuentes F, Su ZY, Kong A-NT. Cancer chemoprevention by traditional chinese herbal medicine and dietary phytochemicals: Targeting NRF2-mediated oxidative stress/anti-inflammatory responses, epigenetics, and cancer stem cells. J Tradit Complement Med 2013; 3(1): 69-79.
[http://dx.doi.org/10.4103/2225-4110.107700] [PMID: 24716158]
[15]
Tsai KC, Huang YC, Liaw CC, et al. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother 2021; 133: 111037.
[http://dx.doi.org/10.1016/j.biopha.2020.111037] [PMID: 33249281]
[16]
Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020; 156: 104761.
[http://dx.doi.org/10.1016/j.phrs.2020.104761] [PMID: 32205232]
[17]
Maslov S, Redner S. Promise and pitfalls of extending Google’s PageRank algorithm to citation networks. J Neurosci 2008; 28(44): 11103-5.
[http://dx.doi.org/10.1523/JNEUROSCI.0002-08.2008] [PMID: 18971452]
[18]
Su H, Yao S, Zhao W, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 2020; 41(9): 1167-77.
[http://dx.doi.org/10.1038/s41401-020-0483-6] [PMID: 32737471]
[19]
Ni L, Wen Z, Hu X, et al. Effects of Shuanghuanglian oral liquids on patients with COVID-19: A randomized, open-label, parallel-controlled, multicenter clinical trial. Front Med 2021; 15(5): 704-17.
[http://dx.doi.org/10.1007/s11684-021-0853-6] [PMID: 33909260]
[20]
Luo L, Jiang J, Wang C, et al. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharm Sin B 2020; 10(7): 1192-204.
[http://dx.doi.org/10.1016/j.apsb.2020.05.007] [PMID: 32834949]
[21]
Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: A rapid review of guidelines. Integr Med Res 2020; 9(2): 100407.
[http://dx.doi.org/10.1016/j.imr.2020.100407] [PMID: 32289016]
[22]
Zhang D, Wu K, Zhang X, Deng S, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med 2020; 18(2): 152-8.
[http://dx.doi.org/10.1016/j.joim.2020.02.005] [PMID: 32113846]
[23]
Sorokina M, Steinbeck C. Review on natural products databases: Where to find data in 2020. J Cheminform 2020; 12(1): 20.
[http://dx.doi.org/10.1186/s13321-020-00424-9] [PMID: 33431011]
[24]
Shi Y, Zhang X, Mu K, et al. D3Targets-2019-nCoV: A webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. Acta Pharm Sin B 2020; 10(7): 1239-48.
[http://dx.doi.org/10.1016/j.apsb.2020.04.006] [PMID: 32318328]
[25]
Ma Q, Liang D, Song S, et al. Comparative study on the antivirus activity of Shuang–Huang–Lian injectable powder and its bioactive compound mixture against human adenovirus III in vitro. Viruses 2017; 9(4): 79.
[http://dx.doi.org/10.3390/v9040079] [PMID: 28417913]
[26]
Li C, Lin G, Zuo Z. Pharmacological effects and pharmacokinetics properties of Radix scutellariae and its bioactive flavones. Biopharm Drug Dispos 2011; 32(8): 427-5.
[http://dx.doi.org/10.1002/bdd.771] [PMID: 21928297]

Rights & Permissions Print Cite
Article Metrics
30
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy